IgM Autoantibodies Can Be Correlated in Cases of Atherosclerosis
|
By LabMedica International staff writers Posted on 20 Feb 2012 |
|
Low levels of immunoglobulin-M (IgM) autoantibodies against lipid phosphorylcholine (PC) add prognostic information in acute coronary syndromes (ACS).
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Thyroid Test
Anti-Thyroid EIA Test
New
Electrolyte Analyzer
BKE-B
Latest Immunology News
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Molecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Microbiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more
